Alteon Inc. announced last week that FDA has requestedamended protocols for its Phase III pivotal clinical trials on itslead compound, aminoguanidine, for treating diabeticneuropathy and end-stage renal disease.

FDA requested that Alteon (NASDAQ:ALTN), of Northvale, N.J.,expand its protocols to include a second treatment arm at anadditional dose -- something that the company is now doing incollaboration with Marion Merrell Dow, its joint partner inclinical development and marketing.

(c) 1997 American Health Consultants. All rights reserved.

No Comments